Matrix Pharmaceutical, Inc.

Syntex (u.s.a.) Inc.

Biomedicines, Inc.

Genentech, Inc.

Chiron Corporation

Syntex LLC

Syntex Pharmaceuticals International Limited

Matrix Pharmaceuticals, Inc.

Richard E Jones

Richard Maskiewicz

Brian H Vickery

Kathleen V Roskos

Keith Adrian Walker

Dennis M Brown

Ning Y Yu

George Trager

Duane W Hallesy

Mike T Li

Shabbir T Anik

James F Maher

Keith Washco

Gisela T Haringer

Jacquelyn A Smithers

Jiin-Yu Hwang-Felgner

Shawnya K Michaels

Saira Singh

Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.

Methods for treating cellular proliferative disorders

Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative diease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Gel delivery vehicles for anticellular proliferative agents

Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative disease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be used in preparing gel formulations for direct injection into a neoplastic lesion or surrounding tissue.

Process and composition for therapeutic cisplatin (CDDP)

Disclosed are proteinaceous compositions comprising collagen and an effective amount of a compatible cytotoxic drug which compositions are characterized by having a single collagen transition temperature of less than about 45.degree. C. Such compositions possess enhanced retention of the cytotoxic drug at the site of injection and are optically translucent.

Collagen formulations

Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically acceptable vehicle capable of acting as a depot. In the subject methods, the chemotherapeutic agent and membrane permeant are administered at least proximal to a target site of the host. Administration of chemotherapeutic agents in accordance with the subject methods results in improved efficacy of, and/or decreased host toxicity to, the intralesionally administered chemotherapeutic agent.

Use of cell membrane permeants in the treatment of cellular

Disclosed are translucent proteinaceous compositions comprising collagen and an effective amount of a compatible cytotoxic drug which compositions are characterized by having a single collagen transition temperature of less than about 45.degree. C. Such compositions possess enhanced retention of the cytotoxic drug at the site of injection and are optically translucent.

Translucent collagen formulations with a cytotoxic drug

Methods and compositions are provided for the treatment of a host with a cellular proliferative disease, particularly a neoplasia. In the subject methods, a pharmaceutically acceptable, substantially anhydrous, injectable semi-solid composition which acts as a depot for a cytostatic agent, is administered to a lesion of the disease, particularly intralesionally. The subject compositions comprise a water immiscible, fatty acid ester matrix and a cytostatic agent.

Methods and compositions for the treatment of a host with a cellular

A liquid pharmaceutical composition comprising an effective amount of non-lyophilized gamma-interferon. The liquid pharmaceutical composition which additionally includes a buffer capable of maintaining the pH of the liquid composition within the range of 4.0 to 6.0, a stabilizing agent and a non-ionic detergent.

Gamma interferon formulation

A unique crystalline polymorphic form of flunisolide is disclosed which is stable in aerosols such as Freon.RTM. mixtures and is valuable in the treatment of respiratory diseases, particularly bronchial asthma and allergic rhinitis.

Stable, crystalline flunisolide

1-Substituted imidazole derivatives exhibit spermatostatic and spermatocidal activity and are useful for contraceptive purposes both in male and female mammals.

Contraceptive compositions and methods employing 1-substituted imidazole

A gel formulation, which is inherently spermicidal and which provides an efficient delivery system for spermicidal and other contraceptively effective compounds intravaginally is disclosed. Said formulation is useful in methods of intravaginal contraception.

Methods and compositions for intravaginal contraception

A unique crystalline form of flunisolide is prepared by crystallizing flunisolide from a solution of an alkanol of three or four carbon atoms, e.g. n-butanol, containing 0.2 to 5%, preferably 1.0 to 4.0% by volume water.

Growing community of inventors

Palo Alto, CA, United States of America

Richard E Jones